Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Huamokang Granules (滑膜康颗粒) is a Traditional Chinese Medicine (TCM) botanical formulation developed by Yabao Pharmaceutical Group for the treatment of traumatic knee synovitis. It is specifically indicated for patients presenting with the "Damp-Heat and Blood Stasis" syndrome (湿热瘀阻证), a classification in TCM characterized by joint swelling, pain, and restricted movement following injury. The formulation is designed to clear heat, resolve dampness, and promote blood circulation to alleviate inflammation in the synovial membrane. As of 2017, the drug was undergoing Phase II clinical trials in China (CTR20170525) to determine optimal dosing and evaluate its safety and therapeutic efficacy in reducing joint effusion and improving functional outcomes compared to standard care or placebo.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on huamokang granules.